{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:42:21Z","timestamp":1790811741465,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["study sponsored by Pfizer"],"award-info":[{"award-number":["study sponsored by Pfizer"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10637-018-0560-6","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:20:07Z","timestamp":1515975607000},"page":"836-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2\/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors"],"prefix":"10.1007","volume":"36","author":[{"given":"Gentry T.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon R.","family":"Beagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Zopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike I.","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"El-Khoueiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ (2017) Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther 34:1\u201321","journal-title":"Adv Ther"},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N (2017) Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat Rev Drug Discov 16:315\u2013337","journal-title":"Nat Rev Drug Discov"},{"key":"560_CR3","doi-asserted-by":"crossref","unstructured":"Lipinski M, Parks DR, Rouse R V, Herzenberg L a (1981) Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A 78:5147\u20135150","DOI":"10.1073\/pnas.78.8.5147"},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1472-6890-12-22","volume":"12","author":"E Bignotti","year":"2012","unstructured":"Bignotti E, Zanotti L, Calza S et al (2012) Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin Pathol 12:22","journal-title":"BMC Clin Pathol"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E et al (2013) Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32:222\u2013233","journal-title":"Oncogene"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, Moser P, Krammel C et al (2008) High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 99:1290\u20131295","journal-title":"Br J Cancer"},{"key":"560_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11605-012-2105-1","volume":"17","author":"S Ning","year":"2013","unstructured":"Ning S, Guo S, Xie J et al (2013) TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg 17:360\u2013368","journal-title":"J Gastrointest Surg"},{"key":"560_CR8","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.18632\/oncotarget.6733","volume":"7","author":"W Zhao","year":"2016","unstructured":"Zhao W, Zhu H, Zhang S et al (2016) Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget 7:6136\u20136145","journal-title":"Oncotarget"},{"key":"560_CR9","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-05-1961","volume":"12","author":"T Ohmachi","year":"2006","unstructured":"Ohmachi T, Tanaka F, Mimori K et al (2006) Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 12:3057\u20133063","journal-title":"Clin Cancer Res"},{"key":"560_CR10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/onc.2012.151","volume":"32","author":"E Guerra","year":"2013","unstructured":"Guerra E, Trerotola M, Aloisi AL et al (2013) The Trop-2 signalling network in cancer growth. Oncogene 32:1594\u20131600","journal-title":"Oncogene"},{"key":"560_CR11","first-page":"309","volume":"1796","author":"R Cubas","year":"2009","unstructured":"Cubas R, Li M, Chen C, Yao Q (2009) Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta - rev. Cancer 1796:309\u2013314","journal-title":"Cancer"},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1158\/1535-7163.MCT-16-0431","volume":"15","author":"P Strop","year":"2016","unstructured":"Strop P, Tran T-T, Dorywalska M et al (2016) RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol Cancer Ther 15:2698\u20132708","journal-title":"Mol Cancer Ther"},{"key":"560_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","volume":"20","author":"P Strop","year":"2013","unstructured":"Strop P, Liu SH, Dorywalska M et al (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20:161\u2013167","journal-title":"Chem Biol"},{"key":"560_CR14","doi-asserted-by":"publisher","first-page":"10527","DOI":"10.1021\/jm501649k","volume":"57","author":"A Maderna","year":"2014","unstructured":"Maderna A, Doroski M, Subramanyam C et al (2014) Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem 57:10527\u201310543. https:\/\/doi.org\/10.1021\/jm501649k","journal-title":"J Med Chem"},{"key":"560_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2531628","volume":"46103149","author":"J O\u2019quigley","year":"1990","unstructured":"O\u2019quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical Design for Phase 1 clinical trials in cancer. Biometrics 46103149:33\u201348","journal-title":"Biometrics"},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2013.54.6051","volume":"32","author":"A Iasonos","year":"2014","unstructured":"Iasonos A, O\u2019Quigley J (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 32:2505\u20132511. https:\/\/doi.org\/10.1200\/JCO.2013.54.6051","journal-title":"J Clin Oncol"},{"key":"560_CR17","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K et al (2011) Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem 59:701\u2013710. https:\/\/doi.org\/10.1369\/0022155411410430","journal-title":"J Histochem Cytochem"},{"key":"560_CR18","doi-asserted-by":"publisher","unstructured":"Ocean AJ, Starodub AN, Bardia A et al (2017) Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. https:\/\/doi.org\/10.1002\/cncr.30789","DOI":"10.1002\/cncr.30789"},{"key":"560_CR19","doi-asserted-by":"publisher","unstructured":"Heist RS, Guarino MJ, Masters G et al (2017) Therapy of advanced non\u2013small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol 35(24):2790\u20132797. https:\/\/doi.org\/10.1200\/JCO.2016.72.1894","DOI":"10.1200\/JCO.2016.72.1894"},{"key":"560_CR20","doi-asserted-by":"publisher","unstructured":"Bardia A, Mayer IA, Diamond JR et al (2017) Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 35(19):2141\u20132148. https:\/\/doi.org\/10.1200\/JCO.2016.70.8297","DOI":"10.1200\/JCO.2016.70.8297"},{"key":"560_CR21","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","volume":"32","author":"PA Ott","year":"2014","unstructured":"Ott PA, Hamid O, Pavlick AC et al (2014) Phase I\/II study of the antibody-drug conjugate Glembatumumab Vedotin in patients with advanced melanoma. J Clin Oncol 32:3659\u20133666. https:\/\/doi.org\/10.1200\/JCO.2013.54.8115","journal-title":"J Clin Oncol"},{"key":"560_CR22","doi-asserted-by":"publisher","unstructured":"Advani RH, Lebovic D, Chen A et al (2017) Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with\/without rituximab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 23:1167\u20131176. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0772","DOI":"10.1158\/1078-0432.CCR-16-0772"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","volume":"28","author":"RM Devay","year":"2017","unstructured":"Devay RM, Delaria K, Zhu G et al (2017) Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug Chem 28:1102\u20131114","journal-title":"Bioconjug Chem"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0560-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:24:07Z","timestamp":1678559047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0560-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0560-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"17 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}